cancer research

The evolution of resistance to diseases, from infectious illnesses to cancers, poses a formidable challenge. Despite the expectation that resistance-conferring mutations would dwindle in the absence of treatment due to a reduced growth rate, preexisting resistance is pervasive across diseases that ...

With a new five-year, $2.78 million grant from the National Institutes of Health and National Cancer Institute, researchers at Case Western Reserve University (CWRU), Cleveland Clinic and University Hospitals (UH) will use artificial intelligence (AI) to better treat rectal cancer patients. The Ame...

Nathan Berger with his wife, Sosamma J. Berger Nathan Berger arrived in Cleveland in 1983 with a vision: creating an oncology/hematology training program to position Case Western Reserve University School of Medicine as a leader in the burgeoning field of cancer care. The program he developed wen...

Fangfang Wang, a postdoctoral scholar in the Department of Pharmacology, was recently awarded an American Cancer Society Postdoctoral Fellowship. Over three years, Wang will study 53BP1 phase separation in genome stability and cancer. Wang is mentored by Youwei Zhang, professor in the Department ...

Neekkan Dey, a postdoc in J. Alan Diehl's group in the Department of Biochemistry at Case Comprehensive Cancer Center, had work accepted for publication in the Molecular Cancer Research Journal by the American Association of Cancer Research. The study, “miR-217 regulates normal and tumor cell fate ...

Case Western Reserve University and MetroHealth cancer researchers have successfully unraveled a mystery surrounding a receptor protein that can either suppress cancer or foster its growth and spread. The findings, recently published in the journal Science, highlight how and why the EphA2 receptor a...

As National Rare Cancer Day nears (Sept. 30), Jed Ian Taxel Foundation for Rare Cancer Research announces major gift to spur cross-country collaboration Less than six months after Jed Ian Taxel’s diagnosis with a rare metastatic cancer, he learned his treatment was ineffective. Weeks before his dea...

Awarded five-year, $3.05 million grant from National Institutes of Health, National Cancer Institute With a new five-year, $3.05 million grant from the National Institutes of Health and National Cancer Institute, researchers at the Case Comprehensive Cancer Center and University Hospitals (UH) will...

A Columbia University oncologist renowned for his translational research, mentoring and leadership will become director of the Case Comprehensive Cancer Center (Case CCC) this spring. Gary Schwartz, chief of the Hematology & Oncology Division at Columbia University Irving Medical Center (CUIMC) and...

Prostate cancer is the leading cancer diagnosis and the second leading cause of cancer-related death among African American/Black men. African American/Black men are roughly twice as likely to be diagnosed with prostate cancer and to die from it as their white counterparts. The Cleveland African Ame...